662. VZV and HSV Vaccines: Why Success with One Alphaherpesvirus But Not the Other?
Session: Symposium: Vaccines Against Herpes Virus
Friday, October 4, 2013: 11:00 AM
Room: The Moscone Center: 130-131 (Hall E)
Thomas Heineman, MD/PhD, Glaxosmithkline Vaccines, King of Prussia, PA

I received a BA (Chemistry), MS (Biochemistry), PhD (Virology) and MD from the University of Chicago. After obtaining my MD, I completed an Internal Medicine residency at the University of Maryland and an Infectious Diseases fellowship at the NIH, where I worked in the laboratory of Dr. Jeffrey Cohen on the molecular biology of varicella-zoster virus. Subsequently, I joined the faculty of the Saint Louis University Division of Infectious Diseases and the Center for Vaccine Development. I worked there as an Assistant and Associate Professor for 11 years on the molecular biology of VZV and on the clinical development of cytomegalovirus and herpes simplex virus vaccines. For the past 7 years, I have worked at GSK Vaccines as the global clinical leader of their HSV, herpes zoster and other herpesvirus vaccine programs.

See more of: Vaccines Against Herpes Virus
See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.